Integrator complex cleavage module (ICM)

The Integrator complex cleavage module (ICM) is a specialized three-subunit protein assembly within the larger Integrator complex, consisting of the catalytic endonuclease Integrator complex subunit 11 (INTS11) and its stabilizing partners INTS9 and INTS4. It functions primarily as an RNA endonuclease that mediates the 3'-end processing of small nuclear RNAs (snRNAs) and regulates the termination of nascent transcripts at protein-coding genes and enhancers. By cleaving RNA as it emerges from RNA polymerase II, the ICM acts as a critical checkpoint for transcriptional attenuation and the biogenesis of various non-coding RNAs. Dysregulation of the ICM is heavily implicated in human disease, particularly in neurodevelopmental disorders where mutations in its subunits lead to severe cognitive and motor deficits. In oncology, the ICM is recognized as a significant therapeutic dependency; for instance, INTS11 has been identified as a synthetic lethal target in 1p36-deleted cancers such as glioblastoma and neuroblastoma. While no FDA-approved drugs currently target the ICM, experimental small-molecule inhibitors targeting the metallo-beta-lactamase domain of INTS11 are under investigation as potential precision medicines for transcription-dependent malignancies.

Other names

Integrator catalytic moduleIntegrator endonuclease moduleINTS4/9/11 complexIntegrator catalytic coreIntegrator nuclease module

Endonucleolytic cleavage of nascent RNA transcripts to facilitate 3'-end maturation or premature transcription termination.